Basic & applied pharmacokinetics self assessment /

Mostrar otras versiones (1)

To exercise the best possible judgment in patient care, medication plans should be selected for the maximum efficacy and safety for each individual patient. Be confident in your approach with ASHP's Basic & Applied Pharmacokinetics Self Assessment, a new resource from John E. Murphy, author...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autor principal: Murphy, John E., 1945- (Autor)
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Bethesda, MD : American Society of Health-System Pharmacists, 2014.
Temas:
Pharmacokinetics > Examinations, questions, etc.
Pharmacokinetics.
Pharmacokinetics
Pharmacocinétique > Examens, questions, etc.
Pharmacocinétique.
MEDICAL > Pharmacology.
Programmed Instruction
programmed textbooks.
Programmed instructional materials
Examinations
Examinations.
Programmed instructional materials.
Matériel d'enseignement programmé.
Acceso en línea:Texto completo
Tabla de Contenidos:
  • Table 1.7-2. Clearance (CL)
  • Table 1.7-3. Digoxin Bioavailability (F) of Dosage Forms
  • Dosing Strategies
  • Estimating Digoxin Clearance (for Adults and Children andgt
  • 12 Years of Age)
  • Estimating Digoxin Dose for a Desired Cssavg (for Adults)
  • Estimating V in Patients with Reduced Renal Function
  • References
  • Self-Assessment Problems
  • Answers
  • 1.8. Unfractionated Heparin and Low Molecular Weight Heparins
  • Heparin Dosing and Monitoring Strategies for Confirmed Venous Thromboembolism
  • Pharmacokinetic/Pharmacodynamic Dosing Approach for UFH Using Activated Clotting Time (ACT)
  • Table 1.8-1. aPTT and Weight-Based Dosing Adjustment Scheme for UFH
  • Table 1.8-2. Protamine Doses for Reversal of LMWH
  • References
  • Self-Assessment Problems
  • Answers
  • 1.9. Lithium
  • Table 1.9-1. Lithium Dosage Forms
  • Table 1.9-2. Select Drug-Drug Interactions
  • Dosing Strategies
  • Dosage and Clearance Prediction Using Demographics
  • References
  • Self-Assessment Problems
  • Table 1.9-3. Recommended Dosages Required to Achieve a Serum Level of 0.6 to 1.2 mEq/L
  • Answers
  • 1.10. Phenobarbital
  • Pharmacokinetic Parameters
  • Table 1.10-1. Volume of Distribution by Age Group
  • Table 1.10-2. Clearance by Age Group
  • Self-Assessment Problems
  • Answers
  • 1.11. Phenytoin/Fosphenytoin
  • Pharmacokinetic Parameters
  • Table 1.11-1. Volume of Distribution
  • Table 1.11-2. Reported Values of Vmax and Km
  • Key Equations
  • Self-Assessment Problems
  • Answers
  • 1.12. Valproic Acid
  • Pharmacokinetic Parameters
  • Table 1.12-1. Clearance by Age in the Absence of Clearance-Altering Factors
  • Table 1.12-2. Bioavailability of Dosage Forms
  • References
  • Self-Assessment Problems
  • Answers
  • 1.13. Vancomycin
  • Pharmacokinetic Parameters
  • Table 1.13-1. Volume of Distribution by Age Group
  • Table 1.13-2. Average Clearance Values.
  • Dosing Strategies
  • Infants
  • Adults
  • AUC
  • References
  • Self-Assessment Problems
  • Answers
  • 1.14. Warfarin
  • Pharmacokinetic Parameters
  • Table 1.14-1. Elimination Half-Lives of Vitamin K-Dependent Proteins
  • Drug-Drug Interactions
  • Table 1.14-2. Select Clinically Significant Warfarin Drug Interactions
  • Dosing Strategies
  • Table 1.14-3. Flexible Initiation Nomogram for Warfarin
  • Table 1.14-4. Warfarin Dosing Adjustment Guidelines for INR Goal of 2-3
  • Self-Assessment Problems
  • Answers
  • SECTION II: SOLUTIONS
  • 2.1. General Pharmacokinetic Applications
  • Solutions
  • 2.2. Medication Dosing in Overweight and Obese Patients
  • Solutions
  • 2.3. Estimating Creatinine Clearance
  • Solutions
  • 2.4. Renal Drug Dosing
  • Solutions
  • 2.5. Aminoglycoside Antibiotics
  • Solutions
  • Estimating k by Estimating Aminoglycoside Clearance (CLag) from Creatinine Clearance
  • Estimating the Peak and Trough Concentrations Using the Population Estimates
  • Estimating k from Estimated Aminoglycoside Clearance (CLag)
  • Estimating the Peak Concentration
  • 2.6. Carbamazepine
  • Solutions
  • 2.7. Digoxin
  • Solutions
  • 2.8. Unfractionated Heparin and Low Molecular Weight Heparins
  • Solutions
  • 2.9. Lithium
  • Solutions
  • 2.10. Phenobarbital
  • Solutions
  • 2.11. Phenytoin/Fosphenytoin
  • Solutions
  • 2.12. Valproic Acid
  • Solutions
  • 2.13. Vancomycin
  • Solutions
  • 2.14. Warfarin
  • Solutions.

Ejemplares similares